Recursion Pharmaceuticals Inc Clas (RXRX) returns
Recursion Pharmaceuticals Inc Clas returns over 5 years
$1,000 invested in Recursion Pharmaceuticals Inc Clas five years ago was worth $210.44 at the close on October 30, 2026, with dividends reinvested: an average return of -26.8% a year. The same $1,000 in the S&P 500 (SPY) became $1,760.
Total return by period
| Period | Total return | A year, on average | $1,000 became | S&P 500 (SPY) |
|---|---|---|---|---|
| 1 month | -2.4% | — | $975.79 | -0.9% |
| 3 months | +32.6% | — | $1,326 | +2.1% |
| Year to date | -1.5% | — | $985.33 | +11.7% |
| 1 year | -28.7% | — | $713.27 | +12.4% |
| 3 years | -24.1% | -8.8% | $758.94 | +88.5% |
| 5 years | -79.0% | -26.8% | $210.44 | +76.0% |
Recursion Pharmaceuticals Inc Clas return by calendar year
| Year | RXRX | S&P 500 (SPY) | Difference |
|---|---|---|---|
| 2026 to date | -1.5% | +11.7% | -13.2% |
| 2025 | -39.5% | +17.7% | -57.2% |
| 2024 | -31.4% | +24.9% | -56.3% |
| 2023 | +27.9% | +26.2% | +1.7% |
| 2022 | -55.0% | -18.2% | -36.8% |
Past returns do not predict future returns. Returns are computed from our daily closes, adjusted for splits and with dividends reinvested on their ex-dates; taxes and trading costs are left out.
See also: RXRX financials
No forecast, no recommendation. This page describes Recursion Pharmaceuticals Inc Clas from published data; it is not advice to buy, sell or hold any security.
Figures as of the close on Oct 30, 2026 unless a row says otherwise. Prices are split adjusted; returns include dividends reinvested. Data may be delayed. See the disclaimer and how TrendArc works.